Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 1;35(4):322-328.
doi: 10.1097/ICU.0000000000001055. Epub 2024 May 1.

Intense pulsed light treatment for the management of meibomian gland dysfunction

Affiliations
Review

Intense pulsed light treatment for the management of meibomian gland dysfunction

Angela Satya Gupta et al. Curr Opin Ophthalmol. .

Abstract

Purpose of review: Meibomian gland dysfunction (MGD) is one of the most common disorders encountered by ophthalmologists, and its management can prove challenging for both clinicians and patients. Intense pulsed light (IPL), which has been historically used in the field of dermatology, has emerged as a tool to help improve meibomian gland function. The goal of this review is to assess the clinical efficacy, utility, and safety of IPL for the treatment of MGD.

Recent findings: In recent randomized controlled trials, IPL has been shown to improve meibomian gland function, and subsequently tear film quality and dry eye symptoms. The mechanism of action still remains unclear. Recent literature suggests that IPL may also be used in conjunction with other therapies, such as meibomian gland expression, low-level light therapy, and thermal pulsation. Careful attention should be placed on each patient's Fitzpatrick skin type, as well as protecting the ocular structures to reduce the risk of adverse effects. Cost, accessibility, as well as a limited duration of efficacy may be drawbacks.

Summary: There is significant evidence supporting that IPL may be used as a potential well tolerated and effective treatment for MGD, though there are certain caveats regarding its long-term efficacy, accessibility, and cost.

PubMed Disclaimer

References

    1. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017; 15:334–365.
    1. Market Scope. 2016 Dry Eye Products Report: a global market analysis for 2015 to 2021. St Louis: Market Scope; 2016.
    1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15:276–283.
    1. Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology 2017; 124:S20–S26.
    1. Lam PY, Shih KC, Fong PY, et al. A review on evidence-based treatments for meibomian gland dysfunction. Eye Contact Lens 2020; 46:3–16.

MeSH terms